SPX6900 (SPX/IDR) Price Today
Key Stats
- Rp6,1TMarket Cap
- Rp132,78MVolume (24h)
- 931M / 1B SPX (94%)Circulating Supply
- 55% Sell | 45% BuyTrading Activity
- 23 DaysTypical Hold Time
Track SPX6900 price today on Pluang, updated in real time with live charts and market data. SPX6900 currently has a market capitalization of Rp6,1T and a 24-hour trading volume of Rp132,78M. SPX6900 has traded between an all-time low of Rp0 and an all-time high of Rp37,269. The circulating supply of SPX6900 stands at 931M / 1B SPX (94%). Recent trading activity shows 55% Sell and 45% Buy, highlighting current market sentiment. On average, investors hold SPX6900 for approximately 23 Days. Buy and sell SPX6900 on Pluang — a safe, fast, and OJK-regulated way to invest in crypto.
About SPX6900
SPX6900 is an advanced blockchain-based cryptography token designed for limitless possibilities and innovative applications. Built to support both practical and scientific use cases, it aims to push the boundaries of blockchain technology through secure, versatile, and future-ready solutions.
Order Book
Shows real-time buy and sell orders, market depth, and short-selling activity to help investors gauge market sentiment.
Most Recent News
Eos Energy posts record Q2 revenue of $68-69M, with order backlog hitting $807M, doubling production capacity.
Eos Energy reported its strongest quarter ever with Q2 2026 revenue projected between $68 million and $69 million, surpassing its full-year 2025 revenue in just the first half of 2026. The company’s order backlog reached an all-time high of $807 mill...
PENGU token unlocks 0.8% supply on July 17, testing market liquidity amid brand strength.
On July 17, 722.96 million PENGU tokens, about 0.8% of total supply, will unlock, potentially impacting market liquidity and price. Previous unlocks, like June 17, caused a 20.6% price drop over ten days, showing supply shocks can influence price if ...
Abbott shares rise 4% as Q2 earnings beat estimates, driven by strong diagnostics growth.
Abbott Laboratories reported better-than-expected Q2 results with adjusted EPS of $1.31 surpassing estimates of $1.28 and revenue rising 13% to $12.59 billion. The diagnostics segment led growth with a 42% surge, fueled by the acquisition of Exact Sc...
People also bought
Frequently Asked Questions
